Best-in-class technology. Tissue-free detection.

Adela is advancing the field of epigenomics to transform how cancer is detected and monitored.

By leveraging proprietary methylome analysis technology and cutting-edge data science, Adela delivers highly sensitive, blood-based tests that uncover critical insights from cell-free DNA.

Our approach enables earlier detection and more precise monitoring of disease, empowering clinicians and partners with the information they need to make confident, informed decisions. At Adela, we are driven to bring clarity to complexity and improve outcomes for patients through innovative, accessible diagnostics.